A TRA诱导缓解治疗急性早幼粒细胞白血病202例。
APL patients were treated with ATRA for induction remission.
结论小儿原发性肾病综合征首用常规激素诱导治疗8周，不缓解者可考虑用大剂量地塞米松冲击治疗。
Conclusion Children's primary nephrotic syndrome should be treated for 8 weeks by routine hormone induction therapy, if no remission, impulsion therapy could be used.
先前未经治疗、而对利妥昔单抗诱导缓解有效后接受延长治疗的患者中，8年有45%患者仍无事件发生。
Of previously untreated patients receiving prolonged treatment after responding to rituximab induction, at 8 years 45% were still without event.
难治性急性白血病对治疗反应差，诱导缓解率低，复发率高，生存期短，是白血病治疗中的难题，目前仍以联合化疗为主要治疗方法。
Bad reaction to treatment, low induced relieving rate, high recurrence rate, and short survival period are tough problem in the treatment of refractory acute leukemia (RAL).
方法：总结92例急性白血病患者在接受诱导缓解化疗、巩固化疗及强化治疗期间的出血表现、血小板计数变化及输注血小板情况。
Methods: Hemorrhagic tendencies, peripheral blood platelet counts and volumes of platelet infusion during different phase of chemotherapy in 92 patients were summarized.
结论TATS对初治及复发APL有一定的诱导分化作用，单药TATS治疗初治及复发apl患者可达到血液学和细胞遗传学缓解。
Conclusion TATS has a differentiation inducing effect on untreated and recurrent APL, with haematological CR and cytogenetic CR achieved.
结论TATS对初治及复发APL有一定的诱导分化作用，单药TATS治疗初治及复发apl患者可达到血液学和细胞遗传学缓解。
Conclusion TATS has a differentiation inducing effect on untreated and recurrent APL, with haematological CR and cytogenetic CR achieved.
应用推荐